MX2024005727A - Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3. - Google Patents
Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.Info
- Publication number
- MX2024005727A MX2024005727A MX2024005727A MX2024005727A MX2024005727A MX 2024005727 A MX2024005727 A MX 2024005727A MX 2024005727 A MX2024005727 A MX 2024005727A MX 2024005727 A MX2024005727 A MX 2024005727A MX 2024005727 A MX2024005727 A MX 2024005727A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- stable formulations
- aqueous pharmaceutical
- stable aqueous
- bcma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277885P | 2021-11-10 | 2021-11-10 | |
| PCT/US2022/079535 WO2023086817A1 (en) | 2021-11-10 | 2022-11-09 | Stable formulations comprising a bispecific bcma/cd3 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005727A true MX2024005727A (es) | 2024-05-27 |
Family
ID=86336796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005727A MX2024005727A (es) | 2021-11-10 | 2022-11-09 | Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230279136A1 (https=) |
| EP (1) | EP4430082A4 (https=) |
| JP (1) | JP2024544523A (https=) |
| KR (1) | KR20240099432A (https=) |
| CN (1) | CN118251417A (https=) |
| AU (1) | AU2022383848A1 (https=) |
| CA (1) | CA3238152A1 (https=) |
| IL (1) | IL312700A (https=) |
| MX (1) | MX2024005727A (https=) |
| TW (1) | TW202328209A (https=) |
| WO (1) | WO2023086817A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005392A (es) | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| WO2024044548A1 (en) * | 2022-08-23 | 2024-02-29 | Janssen Biotech, Inc. | Teclistamab for the treatment of multiple myeloma |
| WO2024044545A1 (en) * | 2022-08-23 | 2024-02-29 | Janssen Biotech, Inc. | Approved products for the treatment of multiple myeloma |
| WO2024231860A1 (en) * | 2023-05-09 | 2024-11-14 | Janssen Biotech, Inc. | Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| CN121712524A (zh) * | 2023-08-18 | 2026-03-20 | 百时美施贵宝公司 | 包含结合bcma和cd3的抗体的组合物以及治疗方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2635352C (en) * | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| UA130542C2 (uk) * | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| US11591395B2 (en) * | 2019-04-19 | 2023-02-28 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti-PSMA/CD3 antibody |
-
2022
- 2022-11-09 KR KR1020247018754A patent/KR20240099432A/ko active Pending
- 2022-11-09 IL IL312700A patent/IL312700A/en unknown
- 2022-11-09 AU AU2022383848A patent/AU2022383848A1/en active Pending
- 2022-11-09 EP EP22893801.5A patent/EP4430082A4/en active Pending
- 2022-11-09 CA CA3238152A patent/CA3238152A1/en active Pending
- 2022-11-09 CN CN202280074899.4A patent/CN118251417A/zh active Pending
- 2022-11-09 US US18/053,904 patent/US20230279136A1/en active Pending
- 2022-11-09 JP JP2024527460A patent/JP2024544523A/ja active Pending
- 2022-11-09 MX MX2024005727A patent/MX2024005727A/es unknown
- 2022-11-09 TW TW111142782A patent/TW202328209A/zh unknown
- 2022-11-09 WO PCT/US2022/079535 patent/WO2023086817A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL312700A (en) | 2024-07-01 |
| EP4430082A4 (en) | 2025-09-03 |
| JP2024544523A (ja) | 2024-12-03 |
| CN118251417A (zh) | 2024-06-25 |
| AU2022383848A1 (en) | 2024-06-27 |
| KR20240099432A (ko) | 2024-06-28 |
| TW202328209A (zh) | 2023-07-16 |
| WO2023086817A1 (en) | 2023-05-19 |
| CA3238152A1 (en) | 2023-05-19 |
| EP4430082A1 (en) | 2024-09-18 |
| US20230279136A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005727A (es) | Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3. | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| CL2021002242A1 (es) | Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) | |
| CL2018002920A1 (es) | Nuevos derivados de pirazolopirimidina | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| CR20190301A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| ECSP23013655A (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr/c-met | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| AR110424A1 (es) | Moléculas de unión a adam9 y métodos de uso de las mismas | |
| CO2024006160A2 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| BR112022011824A2 (pt) | Anticorpos de cadeia pesada que se ligam a cd38 | |
| BR112022008552A2 (pt) | Moléculas de ligação multiespecíficas de scfv de terminal-n | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
| MX2025009913A (es) | Anticuerpos anti-cd3 y metodos para su uso | |
| CL2024001635A1 (es) | Compuestos de diazaspiro sustituidos con carbonilo y su uso | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| BR112022004777A2 (pt) | Composição de micela de estimulação imunológica | |
| CL2023003209A1 (es) | Composición farmacéutica de pembrolizumab y su uso | |
| MX2025010155A (es) | Composiciones que comprenden un anticuerpo biespecifico para gprc5d/cd3 | |
| MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. | |
| CL2025002693A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso. |